A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression

被引：0
|
作者：
Siegfried Kasper
Nicole Praschak-Rieder
Johannes Tauscher
Rainer Wolf
机构：
[1] University of Vienna,Department of General Psychiatry
来源：
Drug Safety | 1997年 / 17卷
关键词：
Adis International Limited; Amitriptyline; Sexual Dysfunction; Mirtazapine; Clomipramine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Mirtazapine is the first of a new class of antidepressants, the noradrenergic and specific serotonergic antidepressants (NaSSA). Its antidepressant effect appears to be related to its dual enhancement of central noradrenergic and serotonin 5-HT1 receptor-mediated serotonergic neurotransmission.
引用
收藏
页码：251 / 264
页数：13
相关论文
共 50 条
  • [21] A risk-benefit assessment of buspirone in the treatment of anxiety disorders
    Pecknold, JC
    DRUG SAFETY, 1997, 16 (02) : 118 - 132
  • [22] Risk-benefit decision making for treatment of depression during pregnancy
    Wisner, KL
    Zarin, DA
    Holmboe, ES
    Appelbaum, PS
    Gelenberg, AJ
    Leonard, HL
    Frank, E
    AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (12): : 1933 - 1940
  • [23] A risk-benefit assessment of losartan potassium in the treatment of hypertension
    Burrell, LM
    DRUG SAFETY, 1997, 16 (01) : 56 - 65
  • [24] A risk-benefit assessment of naltrexone in the treatment of alcohol dependence
    Berg, BJ
    Pettinati, HM
    Volpicelli, JR
    DRUG SAFETY, 1996, 15 (04) : 274 - 282
  • [25] A Risk-Benefit Assessment of Buspirone in the Treatment of Anxiety Disorders
    John C. Pecknold
    Drug Safety, 1997, 16 : 118 - 132
  • [26] A RISK-BENEFIT ASSESSMENT OF CARVEDILOL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
    LOUIS, WJ
    KRUM, H
    CONWAY, EL
    DRUG SAFETY, 1994, 11 (02) : 86 - 93
  • [27] A RISK-BENEFIT ASSESSMENT OF DRUGS USED IN THE TREATMENT OF ENDOMETRIOSIS
    SHAW, RW
    DRUG SAFETY, 1994, 11 (02) : 104 - 113
  • [28] Risk-Benefit Assessment of Foods
    Assuncao, R.
    Pires, S. M.
    Nauta, M.
    EFSA JOURNAL, 2019, 17
  • [29] A RISK-BENEFIT ASSESSMENT OF CELIPROLOL IN THE TREATMENT OF CARDIOVASCULAR-DISEASE
    KENDALL, MJ
    RAJMAN, I
    DRUG SAFETY, 1994, 10 (03) : 220 - 232
  • [30] A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
    Peter Ekman
    Drug Safety, 1998, 18 : 161 - 170
12345